About Aziyo Biologics
Aziyo Biologics is a company based in Silver Spring (United States) founded in 2015. Aziyo Biologics has raised $49.59 million across 6 funding rounds from investors including HighCape Capital, Deerfield and Birchview Capital. The company has 162 employees as of December 31, 2022. Aziyo Biologics offers products and services including CanGaroo, SimpliDerm, and EluPro. Aziyo Biologics operates in a competitive market with competitors including TISSIUM, Theradaptive, MiMedx Group, Ossio and Cardival Medical, among others.
- Headquarter Silver Spring, United States
- Employees 162 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aziyo Biologics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$49.59 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
HighCape Capital
& 2 more
-
Employee Count
162
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aziyo Biologics
Aziyo Biologics offers a comprehensive portfolio of products and services, including CanGaroo, SimpliDerm, and EluPro.
Secures implants like pacemakers to prevent migration and aid healing.
Used for soft tissue repair in reconstruction procedures.
Optimizes stability for cardiac implantable electronic devices.
People of Aziyo Biologics
Unlock access to complete
Unlock access to complete
Funding Insights of Aziyo Biologics
Aziyo Biologics has successfully raised a total of $49.59M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aziyo Biologics
Aziyo Biologics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include HighCape Capital, Deerfield and Birchview Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science companies are targeted for private equity investments.
|
Locked | Locked | Locked | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Business growth and value creation are facilitated by Birchview Capital.
|
Locked | Locked | Locked |
Investor details for Aziyo Biologics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aziyo Biologics
Investment portfolio details for Aziyo Biologics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aziyo Biologics
Detailed financials for Aziyo Biologics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aziyo Biologics Comparisons
Peer comparison for Aziyo Biologics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aziyo Biologics
Aziyo Biologics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TISSIUM, Theradaptive, MiMedx Group, Ossio and Cardival Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Vascular sealants for open surgery are developed by TISSIUM.
|
|
| Locked | Locked | Locked |
Therapeutic delivery platform is developed for orthopedic clinical indications.
|
|
| Locked | Locked | Locked |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics
|
|
| Locked | Locked | Locked |
Orthopedic fixation is enabled by bone regeneration biocomposite technology.
|
|
| Locked | Locked | Locked |
A device for vascular access management is developed.
|
|
| Locked | Locked | Locked |
AV fistula maturation and patency are supported by VasQ device.
|
Detailed competitors of Aziyo Biologics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aziyo Biologics
Complete news archive for Aziyo Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aziyo Biologics
Aziyo Biologics was founded in 2015.
Aziyo Biologics is headquartered in Silver Spring, United States. It is registered at Silver Spring, Maryland, United States.
Ron Lloyd is the current CEO of Aziyo Biologics.
Aziyo Biologics is a funded company, having raised a total of $49.59M across 6 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Aziyo Biologics is 162.
Founded in 2015 and based in Silver Spring, United States, regenerative medicine products are developed by Aziyo Biologics for use in orthopedic, cardiovascular, and other medical specialties. Natural healing mechanisms are leveraged in these products to support clinical applications across multiple sectors. Operations focus on innovation within the biotechnology field, with an emphasis on therapeutic solutions for diverse medical needs.
Aziyo Biologics's top competitors include TISSIUM, EpiBone and Theradaptive.
Aziyo Biologics offers CanGaroo, SimpliDerm, and EluPro.
Aziyo Biologics has 3 investors. Key investors include HighCape Capital, Deerfield, and Birchview Capital.